Reset Font to Default Medium Font Larger Font

Welcome to the McIntyre v. Chelsea Therapeutics International, Ltd., et al. Settlement Website


SETTLEMENT UPDATE
On August 8, 2017, the Net Settlement Fund was distributed to Authorized Claimants whose Claims were approved for payment by the Court and whose proportionate share of the funds available for distribution was $10 or greater as required by the Court-approved Plan of Allocation. If you receive a distribution check, please cash it promptly as it will become stale on the date set forth on the check.


The following is a summary of information presented in more detail in the Settlement Notice, which you can access by clicking on the "Settlement Notice" link to the left.  Since this is just a summary, you should see the full Settlement Notice for additional details.

Please read this information carefully as it explains important rights you may have, including the possible receipt of cash from the Settlement.  If you are a member of the Settlement Class, your legal rights will be affected whether you act or not.
 
This Settlement relates to a securities class action brought by investors who claim that the prices of Chelsea Therapeutics International, Ltd. (“Chelsea”) common stock were artificially inflated as a result of false statements, non-disclosures, and fraudulent conduct in violation of the federal securities laws.  The Settlement provides that Chelsea Therapeutics International, Ltd. will cause $5,500,000 to be paid to the Class.
 
If you purchased or otherwise acquired Chelsea Therapeutics International, Ltd. common stock in the United States or on the NASDAQ Stock Market from September 20, 2010 through May 21, 2012, both dates inclusive, you might be a member of the Class in this Action entitling you to a payment in connection with a settlement of the Action.
 

As provided for in the detailed Settlement Notice, Class Members have a number of options to consider in connection with the Settlement. Class Members may (i) file a claim; (ii) object to the Settlement (with or without appearing at the final approval hearing and with or without hiring your own attorney); (iii) exclude yourself from the Class, or; (iv) do nothing.

IMPORTANT DATES

Submit a Proof of Claim Form  Postmarked no later than September 4, 2016
Exclude Yourself
Deadline has passed.
Object to the Settlement Deadline has passed.
Attend the Hearing September 19, 2016 at 10:00 A.M.
The Settlement was approved.


If you are a Class Member, in order to share in the distribution of the Settlement Fund, you must submit a Proof of Claim form so that it is postmarked no later than September 4, 2016, establishing that you are entitled to recovery.  You can download a Proof of Claim form by clicking on the "Proof of Claim Form" link on the left. NOTE THAT CLAIMS CALCULATING TO AN AWARD AMOUNT LESS THAN $10.00 WILL NOT BE PAID.
 
If you purchased or otherwise acquired CHTP common stock and you desire to be excluded from the Class, you must submit a request for exclusion so that it is received no later than August 29, 2016, in the manner and form explained in the detailed Settlement Notice.  All Class Members who do not timely and validly request exclusion from a Class will be bound by any judgment entered in the Action pursuant to the Stipulation and Agreement of Settlement.
 
If you wish to submit an objection to be considered by the Court, you must file a statement to that effect with the Court and deliver it to counsel by no later than August 29, 2016, in the manner and form explained in the Settlement Notice.
 
If you wish to be heard at the Fairness Hearing, you must submit a "Notice of Intention to Appear at Fairness Hearing in McIntyre v. Chelsea Therapeutics International, Ltd."  Your Notice of Intention to Appear must be filed so it is received by the Court and counsel no later than August 29, 2016, in the manner and form explained in the Settlement Notice.
 
A hearing will be held on September 19, 2016 at 10:00 a.m., before the Honorable Max O. Cogburn, Jr., at the United States Courthouse, 100 Otis Street, Asheville, NC 28801, for the purpose of determining (1) whether the proposed settlement of the claims in the Action for the principal amount of $5,500,000 for the Class should be approved by the Court as fair, just, reasonable, and adequate; (2) whether a Final Judgment and Order of Dismissal with prejudice should be entered by the Court dismissing the Action with prejudice; (3) whether the Plan of Allocation is fair, reasonable, and adequate and should be approved; and (4) whether the application of Lead Counsel for the payment of attorneys’ fees in the amount of 33.3% of the Settlement Fund, an expense award to Lead Plaintiff not to exceed $10,000, and litigation expenses not to exceed $125,000 should be approved. Please note that the date of the Court hearing is subject to change without further notice. If you plan to attend the hearing, you should check with Lead Counsel to be sure no change to the date and time of the hearing has been made.

Disclaimer

THIS SITE IS NOT OPERATED BY CHELSEA THERAPEUTICS INTERNATIONAL, LTD.  THIS SITE IS OPERATED AND ADMINISTERED BY A CLAIMS ADMINISTRATION FIRM THAT HANDLES ALL ASPECTS OF SETTLEMENT NOTIFICATION.  PLEASE DIRECT ANY WEBSITE ERRORS OR QUESTIONS TO THE CLAIMS ADMINISTRATOR, RUST CONSULTING, INC.

View the Privacy Policy